Tesamorelin Research Protocol: Evidence & Vial Reference

Tesamorelin is a GHRH analogue also present in specific licensed medicines for defined indications. Peak's separate 10 mg research vial is not that approved formulation and does not inherit its preparation or administration directions.

Research classification: Research summary · not a validated human regimen. The Tesamorelin 10 mg vial label reports nominal content; it does not state a suitable amount for human use.

In test subjects, tesamorelin binds GHRH receptors to stimulate endogenous GH release, with research interest in visceral adipose tissue reduction.

Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.

The earlier catalogue entry described research examples, not a clinically validated schedule for people. The dose, route, frequency or escalation used in one experiment cannot be generalised to a different formulation or to an individual. When primary evidence is not available, do not treat a catalogue number as a recommendation.

For the existing schedule, its evidence caveats and the concentration calculator, see the Tesamorelin protocol and vial reference. Figures displayed there are research context, not a personalised prescription.

An exact-matching Peak Peptides Australia 10 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.

Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.

View Peak Peptides Australia's research-only listing and confirm its current labelled strength.

• Falutz J et al. Tesamorelin for visceral adiposity. NEJM 2007 — NEJM

For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.